June 5, 2014
-- In the spirit of its mission to improve people's lives,
(NYSE: SAP) today announced that it intends to offer a personalized treatment option service, in collaboration with MolecularHealth and GATC Biotech, to qualified employees fighting cancer.
The service would be based on MolecularHealth's TreatmentMAP™
software and generate an individual tumor analysis for each patient, providing a clinical interpretation of the clinical and genomic patient data to support their physician in making an individualized treatment decision. In
, sequencing data is planned to be provided by GATC Biotech; and in
the United States
, MolecularHealth intends to run its own CLIA-certified sequencing lab. These huge amounts of data would be processed with an ultra-fast genome alignment algorithm, which is part of the SAP® Genomic Analyzer solution and used to assemble the full exome DNA sequence in three minutes — about 300 times faster than the alignment software previously used.
Treatment options based on sequencing data processed by MolecularHealth's TreatmentMAP powered by the SAP HANA® platform are anticipated to be delivered to the oncologists treating SAP employees. It is then up to the oncologist and patient to confer and decide upon an appropriate course of action, but they would be armed with additional information which may not have been otherwise available. MolecularHealth's TreatmentMAP software is the first registered medical device of its kind in
for personalized cancer medicine.
SAP is planning to offer this service to employees who have been diagnosed with a solid tumor cancer. It is planned to be piloted for employees in two countries, with employees in additional countries gaining the benefit in the future. SAP hopes to convince other employers to consider offering such a benefit.